![Josefin-Beate Holz](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Josefin-Beate Holz
No más puestos en curso
Historial de carrera de Josefin-Beate Holz
Antiguos cargos conocidos de Josefin-Beate Holz.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ABLYNX | Director Técnico/Científico/I+D | 27/05/2009 | 30/06/2013 |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Corporate Officer/Principal | - | - |
Formación de Josefin-Beate Holz.
Philipps University of Marburg | Doctorate Degree |
Estadísticas
Internacional
Alemania | 3 |
Bélgica | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 2 |
Commercial Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Ablynx NV
![]() Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Commercial Services |
- Bolsa de valores
- Insiders
- Josefin-Beate Holz
- Experiencia